Coronavirus Disease 2019 (COVID-19)
FDA is working with U.S. government partners, including CDC, and international partners to address the pandemic.
Topic Paragraphs
Featured Topics
FDA Monkeypox Response
The FDA’s multipronged response to monkeypox includes efforts in the areas of diagnostics, vaccines and therapeutics.
Infant Formula Information and Resources
The FDA continues to work around the clock with our government partners and industry to ensure there's adequate infant formula available wherever and whenever parents and caregivers need it.
Recent Press Announcements
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Dec 06
Cranberry Sweets & More Issues Allergy Alert On Undeclared Peanuts In “Mint Meltaways”
Food & Beverages
Dec 06
LIDL Voluntarily Recalls 8.4 Oz Favorina Branded Advent Calendar (Premium Chocolate with a Creamy Filling) Due to Potential Salmonella Contamination
Food & Beverages
Dec 03
Exportadora Copramar Recalls James Farms Frozen Raspberries Due to Possible Health Risk
Food & Beverages
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
FDA’s Cybersecurity Modernization Action Plan
CMAP will leverage Artificial Intelligence and Machine Learning technologies to enhance cyber detection and response capabilities.
Focusing on Prevention to Safeguard Infant Formula
FDA is working with infant formula manufacturers to maximize production and taking steps to assure the public that infant formula is and will remain safe.
FDA Continues to Advance Medicines for Children
Increasing the availability of safe and effective medicines for children is a key priority for the U.S. Food and Drug Administration.
Recently Published Guidances
Dec 06
Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer
Drugs
Dec 05
E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials
Dec 02
Statistical Approaches to Establishing Bioequivalence
Drugs